Dr Taylor Wallace
Taylor C. Wallace, PhD, CFS, FACN, is Principal and CEO at the Think Healthy Group and a Professor in the Department of Nutrition and Food Studies at George Mason University. Prior to founding the Think Healthy Group, Dr. Wallace served as the Senior Director of Science Policy and Government Relations at the National Osteoporosis Foundation (NOF) and the Senior Director of Scientific Programs at the National Bone Health Alliance (NBHA), a public-private partnership, managed and operated by the NOF. He has extensive experience in developing and implementing comprehensive and evidence-based legislative, policy, and regulatory programs in the fields of nutrition and food science. His academic research interests are in the area of nutritional interventions to promote health and prevent the onset of chronic disease. Dr. Wallace’s background includes a PhD and an MS in Food Science and Nutrition from The Ohio State University and a BS in Food Science and Technology from the University of Kentucky. In his free time, Dr. Wallace manages and operates a large food and nutrition blog, www.DrTaylorWallace.com, where he provides science-based nutrition, food safety, and food technology information to the general public and consumer media. Dr. Wallace has served on the Boards of Directors for the Institute of Food Technologists, Alliance for Food and Health, Feeding Tomorrow, and Phi Tau Sigma. He is a fellow of the American College of Nutrition and is the 2015 recipient of the Charles A. Regus Award, given by the American College of Nutrition for original research and innovation in the field of nutrition. Dr. Wallace is a Senior Fellow of the Center for Magnesium Education & Research, the Deputy Editor in Chief of the Journal of the American College of Nutrition, Editor in Chief of the Journal of Dietary Supplements, the editor of six academic textbooks, and an author of over 40 peer-reviewed manuscripts and
Dr Chandrabali Ghose
John Hambor
Dr Biswajit Biswas
Dr David Harper
My day job is as the CEO of Evolution Biotechnologies, moving environmentally friendly biological controls into the biomedical sector, based on the success of such agents in agriculture. This is based around low cost approaches minimising investor dilution while moving towards large potential markets.
Targets include the house dust mite, the main cause of asthma, where our novel approach underlies broad patent protection, and antibiotic resistant bacterial infections where individual veterinary treatments are already being undertaken. The company is building on its unique skillset in these key areas.
Betty Kutter
Dr Kevin Yehl
Dr Joe Campbell
I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID’s bacteriophage interest group. The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.
Prof Thomas Patterson
Dr Steffanie Strathdee
Dr. Strathdee is an infectious disease epidemiologist who received her doctoral training at the University of Toronto. She is renowned for her research on the intersection of HIV and drug use, having generated >600 scholarly publications. She is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego where she codirects the Center for Innovative Phage Applications and Therapeutics. She is married to Thomas L. Patterson, Professor of Psychiatry at UC San Diego, where they co-direct a research and training program on the Mexico-US border.
Strathdee was recently credited with saving her husband’s life from a deadly superbug infection using bacteriophages –viruses that attack bacteria. The case, which involved cooperation from three universities, the U.S. Navy and researchers across the globe, shows how phage therapy is a future weapon against multi-drug resistant bacterial infections which are expected to kill 10 million people per year by 2050. Strathdee and Patterson co-authored a book on their story called The Perfect Predator: A Scientist’s Race to Save Her Husband from a Deadly Superbug.